Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated Cardiomyopathy

NCT ID: NCT07293338

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

330 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-06

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to learn about the long-term prognostic of coronary microvascular dysfuction in Patients with Dilated Cardiomyopathy.

The main question it aims to answer is: Does the coronary microvascular dysfunction impact the outcomes in Patients with Dilated Cardiomyopathy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dilated Cardiomyopathy (DCM)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Coronary microvascular dysfunction

coronary angiography

Intervention Type PROCEDURE

Patients should undergo coronary angiography to confirm the absence of significant coronary stenosis. Angio-IMR was calculated based on the angiography.

Non-Coronary microvascular dysfunction

coronary angiography

Intervention Type PROCEDURE

Patients should undergo coronary angiography to confirm the absence of significant coronary stenosis. Angio-IMR was calculated based on the angiography.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

coronary angiography

Patients should undergo coronary angiography to confirm the absence of significant coronary stenosis. Angio-IMR was calculated based on the angiography.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Dilated cardiomyopathy comfirmed by echocardiography: LVDd \> 55 mm in men or \> 50 mm in women.
* Clinically evident congestive heart failure: Compatible symptoms and signs, and BNP ≥ 35 pg/mL or NT-proBNP ≥ 125 pg/mL, and LV systolic dysfunction defined by LVEF \< 45 %.
* Coronary angiography showing stenosis ≤ 50 % in all major epicardial vessels.

Exclusion Criteria

* Patients with coronary artery disease, hypertensive heart disease, rheumatic valvular heart disease, myocarditis, and other secondary cardiomyopathies.
* poor angiographic image quality
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The second affiliated hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jun Jiang, MD

Role: CONTACT

Phone: +86 15657125311

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jun Jiang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-0971

Identifier Type: -

Identifier Source: org_study_id